Author, Subjects, Keywords

Cited Author

 

 
   » By Author or Editor
 » Browse Author by Alphabet
 » By Journal
 » By Subjects
 » Malaysian Journals
 » By Type
 » By Year
 » By Latest Additions
 
 
   » By Author
 » Top 20 Authors
 » Top 20 Article
 » Top Journal Cited
 » Top Article Cited
 » Journal Citation Statistics
 » Usage Since Sept 2007


 
 
 

Login | Create Account

Cases of melioidosis in a university teaching hospital in Malaysia

Raja, Nadeem Sajjad, (2008) Cases of melioidosis in a university teaching hospital in Malaysia. Journal of Microbiology, Immunology and Infection , 41 (2). pp. 174-179.

Full text not available from this repository.

Official URL: http://www.jmii.org/content/pdf/v41n2p174.pdf

Affiliations

University of Malaya Medical Centre. Dept. of Medical Microbiology

Abstract

Melioidosis is an infectious disease caused by Burkholderia pseudomallei that is endemic in Southeast Asia and northern Australia and has also been reported from non-endemic areas of the world. Little is known about the antimicrobial susceptibility pattern and the demography of melioidosis patients in Malaysia. This was a retrospective study of 83 patients with culture-proven B. pseudomallei infections from the University of Malaya Medical Centre, Kuala Lumpur, Malaysia from May 1995 to June 2005. Antimicrobial susceptibility of B. pseudomallei, age, gender and race of patients, nature of specimen, serological evidence and monthly distribution of cases were evaluated. All isolates were susceptible to piperacillin and piperacillin-tazobactam. The majority of strains were susceptible to imipenem (99%), ceftazidime (94%), amoxicillin-clavulanic acid (95%), ampicillin-sulbactam (94%), tetracycline (89%), chloramphenicol (94%), trimethoprim-sulfamethoxazole (70%), meropenem (88%) and ciprofloxacin (79%). Significant antimicrobial resistance was noted in aminoglycosides and ampicillin. The male-to-female ratio was 3.15:1, and mean age was 43.85 years. The majority of the patients were middle-aged (41-60 years). Malays and Indians made up 39% and 33% of affected patients, while Chinese and others comprised 25% and 3%, respectively. Of 83 patients, 67 were diagnosed by positive blood cultures, and 16 patients were non-bacteremic cases. There were 22 patients in whom B. pseudomallei grew in more than one clinical specimen, and there were 6 polymicrobial cases. Melioidosis is expanding in endemicity around the world. Control of the disease requires close monitoring, improved clinical laboratory standards and aggressive therapy.

Item Type:Journal
Keywords:Burkholderia pseudomallei; Malaysia; Melioidosis
Subjects:Q Science, Computer Science
R Medicine, Dentistry, Pharmacy, Nursing
ID Code:3362

1. Issack MI, Bundhun CD, Gokhool H. Melioidosis in Mauritius. Emerg Infect Dis. 2005;11:139-40.

2. Raja NS, Ahmed MZ, Singh NN. Melioidosis: an emerging infectious disease. J Postgrad Med. 2005;51:140-5.

3. Cheng AC, Godoy D, Mayo M, Gal D, Spratt BG, Currie BJ. Isolates of Burkholderia pseudomallei from Northern Australia are distinct by multilocus sequence typing, but strain types do not correlate with clinical presentation. J Clin Microbiol. 2004;42:5477-83.

4. Dance DA. Melioidosis as an emerging global problem. Acta Trop. 2000;74:115-9.

5. Barnes JL, Ketheesan N. Route of infection in melioidosis. Emerg Infect Dis. 2005;11:638-9.

6. Abbink FC, Orendi JM, de Beaufort AJ. Mother-to-child transmission of Burkholderia pseudomallei. N Engl J Med. 2001;344:1171-2.

7. Ralph A, McBride J, Currie BJ. Transmission of Burkholderia pseudomallei via breast milk in northern Australia. Pediatr Infect Dis J. 2004;23:1169-71.

8. Brett PJ, Woods DE. Pathogenesis of and immunity to melioidosis. Acta Trop. 2000;74:201-10.

9. Currie BJ, Fisher DA, Howard DM, Burrow JN. Neurological melioidosis. Acta Trop. 2000;74:145-51.

10. Cheng AC, Fisher DA, Anstey NM, Stephens DP, Jacups SP, Currie BJ. Outcomes of patients with melioidosis treated with meropenem. Antimicrob Agents Chemother. 2004;48:1763-5.

11. How HS, Ng KH, Yeo HB, Tee HP, Shah A. Pediatric melioidosis in Pahang, Malaysia. J Microbiol Immunol Infect. 2005;38:314-9.

12. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement. CLSI document M100-S14. Wayne, PA: Clinical and Laboratory Standards Institute;2006.

13. Vadivelu J, Puthucheary SD, Gendeh GS, Parasakthi N. Serodiagnosis of melioidosis in Malaysia. Singapore Med J. 1995;36:299-302.

14. Vadivelu J, Puthucheary SD. Diagnostic and prognostic value of an immunofluorescent assay for melioidosis. Am J

Trop Med Hyg. 2000;62:297-300.

15. Kishimoto RA, Brown GL, Blair EB, Wenkheimer D. Melioidosis: serologic studies on US Army personnel returning from Southeast Asia. Mil Med. 1971;136:694-8.

16. Currie BJ, Fisher DA, Howard DM, Burrow JN, Lo D, Selva-Nayagam S, et al. Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin Infect Dis. 2000;31:981-6.

17. Orellana C. Melioidosis strikes Singapore. Lancet Infect Dis. 2004;4:655.

18. Thomas AD, Forbes-Faulkner J, Parker M. Isolation of Pseudomonas pseudomallei from clay layers at defined depths. Am J Epidemiol. 1979;110:515-21.

19. Currie BJ, Jacups SP. Intensity of rainfall and severity of melioidosis, Australia. Emerg Infect Dis. 2003;9:1538-42.

20. Suputtamongkol Y, Hall AJ, Dance DA, Chaowagul W, Rajchanuvong A, Smith MD, et al. The epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand. Int J Epidemiol. 1994;23:1082-90.

21. Guard RW, Khafagi FA, Brigden MC, Ashdown LR. Melioidosis in Far North Queensland. A clinical and epidemiological review of twenty cases. Am J Trop Med Hyg. 1984;33:467-73.

22. Jesudason MV, Anbarasu A, John TJ. Septicaemic melioidosis in a tertiary care hospital in south India. Indian J Med Res. 2003;117:119-21.

23. Hsueh PR, Teng LJ, Lee LN, Yu CJ, Yang PC, Ho SW, et al. Melioidosis: an emerging infection in Taiwan? Emerg Infect Dis. 2001;7:428-33.

24. Raja NS. Localized melioidosis. J Pak Med Assoc. 2003; 53:373-4.

25. White NJ, Dance DA, Chaowagul W, Wattanagoon Y, Wuthiekanun V, Pitakwatchara N. Halving of mortality of severe melioidosis by ceftazidime. Lancet. 1989;2:697-701.

26. Puthucheary SD, Parasakthi N. Antimicrobial susceptibility of Pseudomonas pseudomallei. J Antimicrob Chemother. 1987;20:921-2.

27. Dance DA, Wuthiekanun V, Chaowagul W, Suputtamongkol Y, White NJ. Development of resistance to ceftazidime and co-amoxiclav in Pseudomonas pseudomallei. J Antimicrob Chemother. 1991;28:321-4.

28. Kenny DJ, Russell P, Rogers D, Eley SM, Titball RW. In vitro susceptibilities of Burkholderia mallei in comparison to those of other pathogenic Burkholderia spp. Antimicrob Agents Chemother. 1999;43:2773-5.

29. Inglis TJ, Rodrigues F, Rigby P, Norton R, Currie BJ. Comparison of the susceptibilities of Burkholderia pseudomallei to meropenem and ceftazidime by conventional and intracellular methods. Antimicrob Agents Chemother. 2004;48:2999-3005.

30. White NJ. Melioidosis. Lancet. 2003;361:1715-22. 31. Smith MD, Wuthiekanun V, Walsh AL, White NJ. In-vitro activity of carbapenem antibiotics against beta-lactam susceptible and resistant strains of Burkholderia

pseudomallei. J Antimicrob Chemother. 1996;37:611-5.

32. Dance DA, Wuthiekanun V, Chaowagul W, White NJ. The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J Antimicrob Chemother. 1989;24:295-309.

33. Simpson AJ, Suputtamongkol Y, Smith MD, Angus BJ, Rajanuwong A, Wuthiekanun V, et al. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin Infect Dis. 1999;29:381-7.

34. Yamamoto T, Naigowit P, Dejsirilert S, Chiewsilp D, Kondo E, Yokota T, et al. In vitro susceptibilities of Pseudomonas pseudomallei to 27 antimicrobial agents. Antimicrob Agents Chemother. 1990;34:2027-9.

35. Chaowagul W, Simpson AJ, Suputtamongkol Y, Smith MD, Angus BJ, White NJ. A comparison of chloramphenicol, trimethoprim-sulfamethoxazole, and doxycycline with doxycycline alone as maintenance therapy for melioidosis. Clin Infect Dis. 1999;29:375-80.

36. Chaowagul W, Chierakul W, Simpson AJ, Short JM, Stepniewska K, Maharjan B, et al. Open-label randomized trial of oral trimethoprim-sulfamethoxazole, doxycycline and chloramphenicol compared with imethoprimsulfamethoxazole

and doxycycline for maintenance therapy of melioidosis. Antimicrob Agents Chemother. 2005;49:4020-5.

37. Chaowagul W, Suputtamongkul Y, Smith MD, White NJ. Oral fluoroquinolones for maintenance treatment of melioidosis. Trans R Soc Trop Med Hyg. 1997;91:599-601.

38. Jenney AW, Lum G, Fisher DA, Currie BJ. Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis.Int J Antimicrob Agents. 2001;17:109-13.

39. Chetchotisakd P, Chaowagul W, Mootsikapun P, Budhsarawong D, Thinkamrop B. Maintenance therapy of melioidosis with ciprofloxacin plus azithromycin compared with cotrimoxazole plus doxycycline. Am J Trop Med Hyg.

2001;64:24-7.

Repository Staff Only: item control page